Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087
   PubMed Web of Science ®Google Scholar
• Matsumura N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamanishi J, Kang HS, Matsui S, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010; 101:2658-63; PMID:21040214; http://dx.doi.org/10.1111/j.1349-7006.2010.01736.x
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16(Suppl 2):S17-27; PMID:22443084; http://dx.doi.org/10.1517/14728222.2011.639361
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011; 11:50-7; PMID:21057220; http://dx.doi.org/10.4161/cbt.11.1.13877
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7004-14; PMID:12242281; http://dx.doi.org/10.1128/MCB.22.20.7004-7014.2002
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-72; PMID:11292861; http://dx.doi.org/10.1126/science.1059796
   PubMed Web of Science ®Google Scholar
• Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66:2000-11; PMID:16488999; http://dx.doi.org/10.1158/0008-5472.CAN-05-3074
   PubMed Web of Science ®Google Scholar
• Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, et al. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther 2010; 10:1137-46; PMID:20935474; http://dx.doi.org/10.4161/cbt.10.11.13443
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68:7409-18; PMID:18794129; http://dx.doi.org/10.1158/0008-5472.CAN-08-1522
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36:320-8; PMID:21531565; http://dx.doi.org/10.1016/j.tibs.2011.03.006
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74; PMID:18725988
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-37; PMID:15728109; http://dx.doi.org/10.1093/annonc/mdi113
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15:5404-13; PMID:19690197; http://dx.doi.org/10.1158/1078-0432.CCR-09-0365
   PubMed Web of Science ®Google Scholar
• Fujisue Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Azuma H, Asahi M. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett 2013; 5:1765-70; PMID:23833638
   PubMed Web of Science ®Google Scholar
• Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992; 89:3070-4; PMID:1348364; http://dx.doi.org/10.1073/pnas.89.7.3070
   PubMed Web of Science ®Google Scholar
• Bae D, Ceryak S. Raf-independent, PP2A-dependent MEK activation in response to ERK silencing. Biochem Biophys Res Commun 2009; 385:523-7; PMID:19465001; http://dx.doi.org/10.1016/j.bbrc.2009.05.082
   PubMed Web of Science ®Google Scholar
• Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, Xu Z, Han X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 2010; 101:1226-33; PMID:20331621; http://dx.doi.org/10.1111/j.1349-7006.2010.01523.x
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22; PMID:12509763; http://dx.doi.org/10.1038/nrc969
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64:7678-81; PMID:15520168; http://dx.doi.org/10.1158/0008-5472.CAN-04-2933
   PubMed Web of Science ®Google Scholar
• Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174:1597-601; PMID:19349352; http://dx.doi.org/10.2353/ajpath.2009.081000
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39:231-4; PMID:17551816; http://dx.doi.org/10.1007/s10863-007-9081-2
   PubMed Web of Science ®Google Scholar
• Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets 2013; 13:245-51; PMID:23297826; http://dx.doi.org/10.2174/1568009611313030003
   PubMed Web of Science ®Google Scholar
• Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14:4726-34; PMID:18676741; http://dx.doi.org/10.1158/1078-0432.CCR-07-4921
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8; PMID:16452206; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925
   PubMed Web of Science ®Google Scholar
• Adams DG, Coffee RL Jr., Zhang H, Pelech S, Strack S, Wadzinski BE. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem 2005; 280:42644-54; PMID:16239230; http://dx.doi.org/10.1074/jbc.M502464200
   PubMed Web of Science ®Google Scholar
• Fukukawa C, Tanuma N, Okada T, Kikuchi K, Shima H. pp32/ I-1(PP2A) negatively regulates the Raf-1/MEK/ERK pathway. Cancer Lett 2005; 226:155-60; PMID:16039954; http://dx.doi.org/10.1016/j.canlet.2004.11.026
   PubMed Web of Science ®Google Scholar
• Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem 2005; 280:36029-36; PMID:16129692; http://dx.doi.org/10.1074/jbc.M506986200
   PubMed Web of Science ®Google Scholar
• Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-32; PMID:12878853; http://dx.doi.org/10.4161/cbt.2.3.360
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917
   PubMed Web of Science ®Google Scholar
• Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431:200-5; PMID:15306821; http://dx.doi.org/10.1038/nature02866
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, et al. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther 2013; 12:1367-77; PMID:23615631; http://dx.doi.org/10.1158/1535-7163.MCT-12-1185
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Asahi M. beta1-adrenergic receptor recycles via a membranous organelle, recycling endosome, by binding with sorting nexin27. J Membr Biol 2013; 246:571-9; PMID:23780416; http://dx.doi.org/10.1007/s00232-013-9571-6
   PubMed Web of Science ®Google Scholar